291 related articles for article (PubMed ID: 9403621)
21. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
Hill NS; Warburton RR; Pietras L; Klinger JR
J Appl Physiol (1985); 1997 Oct; 83(4):1209-15. PubMed ID: 9338430
[TBL] [Abstract][Full Text] [Related]
22. Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure.
Jiang BH; Tardif JC; Shi Y; Dupuis J
Eur Respir J; 2011 Mar; 37(3):578-86. PubMed ID: 20595149
[TBL] [Abstract][Full Text] [Related]
23. Endothelin receptor blockade reduces ventricular dysfunction and injury after reoxygenation.
Pearl JM; Nelson DP; Wagner CJ; Lombardi JP; Duffy JY
Ann Thorac Surg; 2001 Aug; 72(2):565-70. PubMed ID: 11515898
[TBL] [Abstract][Full Text] [Related]
24. Long-term endothelin receptor blockade improves cardiovascular function in diabetes.
Verma S; Arikawa E; McNeill JH
Am J Hypertens; 2001 Jul; 14(7 Pt 1):679-87. PubMed ID: 11465653
[TBL] [Abstract][Full Text] [Related]
25. Myocardial contractile responsiveness to endothelin-1 in the post-infarction rat model of heart failure: effects of chronic quinapril.
Qi XL; Sia YT; Stewart DJ; Wei G; Nguyen QT; Cernacek P; Picard P; Sirois M; Rouleau JL
J Mol Cell Cardiol; 2001 Nov; 33(11):2023-35. PubMed ID: 11708846
[TBL] [Abstract][Full Text] [Related]
26. Chronic administration of an endothelin-A receptor antagonist improves exercise capacity in rats with myocardial infarction-induced congestive heart failure.
Miyauchi T; Fujimori A; Maeda S; Iemitsu M; Sakai S; Shikama H; Tanabe T; Matsuda M; Goto K; Yamaguchi I
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S64-7. PubMed ID: 15838361
[TBL] [Abstract][Full Text] [Related]
27. Long-term effects of beta-adrenergic blocking agent treatment on hemodynamic function and left ventricular remodeling in rats with experimental myocardial infarction: importance of timing of treatment and infarct size.
Hu K; Gaudron P; Ertl G
J Am Coll Cardiol; 1998 Mar; 31(3):692-700. PubMed ID: 9502655
[TBL] [Abstract][Full Text] [Related]
28. Cardioprotective effects of bosentan, a mixed endothelin type A and B receptor antagonist, during myocardial ischaemia and reperfusion in rats.
Singh AD; Amit S; Kumar OS; Rajan M; Mukesh N
Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):604-10. PubMed ID: 16700825
[TBL] [Abstract][Full Text] [Related]
29. Endothelin-receptor blockade improves endothelial vasomotor dysfunction in heart failure.
Bauersachs J; Fraccarollo D; Galuppo P; Widder J; Ertl G
Cardiovasc Res; 2000 Jul; 47(1):142-9. PubMed ID: 10869540
[TBL] [Abstract][Full Text] [Related]
30. Blockade of endothelin receptors attenuates end-organ damage in homozygous hypertensive ren-2 transgenic rats.
Dvorák P; Kramer HJ; Bäcker A; Malý J; Kopkan L; Vanecková I; Vernerová Z; Opocenský M; Tesar V; Bader M; Ganten D; Janda J; Cervenka L
Kidney Blood Press Res; 2004; 27(4):248-58. PubMed ID: 15286437
[TBL] [Abstract][Full Text] [Related]
31. Bosentan, the mixed ETA-ETB endothelin receptor antagonist, attenuated oxidative stress after experimental myocardial ischemia and reperfusion.
Gupta SK; Saxena A; Singh U; Arya DS
Mol Cell Biochem; 2005 Jul; 275(1-2):67-74. PubMed ID: 16335785
[TBL] [Abstract][Full Text] [Related]
32. Endothelin-1 receptor antagonism does not influence myocardial function in hypertensive dogs.
Massart PE; Hodeige D; Van Mechelen H; Heyndrickx GR; Donckier J
Eur J Clin Invest; 1998 Oct; 28(10):798-806. PubMed ID: 9792992
[TBL] [Abstract][Full Text] [Related]
33. Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats.
Lourenço AP; Roncon-Albuquerque R; Brás-Silva C; Faria B; Wieland J; Henriques-Coelho T; Correia-Pinto J; Leite-Moreira AF
Am J Physiol Heart Circ Physiol; 2006 Oct; 291(4):H1587-94. PubMed ID: 16679394
[TBL] [Abstract][Full Text] [Related]
34. Effects of imidapril on endothelin-1 and ACE gene expression in failing hearts of salt-sensitive hypertensive rats.
Kobayashi N; Hara K; Higashi T; Matsuoka H
Am J Hypertens; 2000 Oct; 13(10):1088-96. PubMed ID: 11041163
[TBL] [Abstract][Full Text] [Related]
35. Renal endothelin system in polycystic kidney disease.
Hocher B; Zart R; Schwarz A; Vogt V; Braun C; Thöne-Reineke C; Braun N; Neumayer HH; Koppenhagen K; Bauer C; Rohmeiss P
J Am Soc Nephrol; 1998 Jul; 9(7):1169-77. PubMed ID: 9644626
[TBL] [Abstract][Full Text] [Related]
36. Effects of a novel angiotensin AT(1) receptor antagonist, HR720, on rats with myocardial infarction.
Xia QG; Chung O; Spitznagel H; Sandmann S; Illner S; Rossius B; Jähnichen G; Reinecke A; Gohlke P; Unger T
Eur J Pharmacol; 1999 Dec; 385(2-3):171-9. PubMed ID: 10607873
[TBL] [Abstract][Full Text] [Related]
37. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.
Schieffer B; Wirger A; Meybrunn M; Seitz S; Holtz J; Riede UN; Drexler H
Circulation; 1994 May; 89(5):2273-82. PubMed ID: 8181153
[TBL] [Abstract][Full Text] [Related]
38. Effect of endurance training early or late after coronary artery occlusion on left ventricular remodeling, hemodynamics, and survival in rats with chronic transmural myocardial infarction.
Gaudron P; Hu K; Schamberger R; Budin M; Walter B; Ertl G
Circulation; 1994 Jan; 89(1):402-12. PubMed ID: 8281676
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of the mixed ET(A)/ET(B)-receptor antagonist bosentan on endothelin-induced bronchoconstriction, vasoconstriction and prostacyclin release.
Martin C; Held HD; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2000 Aug; 362(2):128-36. PubMed ID: 10961375
[TBL] [Abstract][Full Text] [Related]
40. Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats.
Smith PJ; Ornatsky O; Stewart DJ; Picard P; Dawood F; Wen WH; Liu PP; Webb DJ; Monge JC
Circulation; 2000 Dec; 102(24):2983-9. PubMed ID: 11113050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
